China Pharma Holdings (CPHI) Accumulated Expenses (2010 - 2026)

China Pharma Holdings has reported Accumulated Expenses for 17 years, with the latest figure at $311336.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 59.44% year-over-year to $311336.0; the trailing twelve-month figure through Mar 2026 stood at $311336.0 (up 59.44% YoY), and the FY2025 full-year result was $350643.0, up 41.87% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $311336.0, down from $350643.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $1.3 million in Q3 2024, with the low at $110387.0 in Q2 2022.
• Historically, Accumulated Expenses has averaged $263402.3 across 5 years, with a median of $191293.0 in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Expenses surged 949.15% — and 2025, when it sank 86.43%.
• China Pharma Holdings' Accumulated Expenses stood at $404807.0 in 2022, then slipped by 26.18% to $298829.0 in 2023, then decreased by 17.29% to $247159.0 in 2024, then soared by 41.87% to $350643.0 in 2025, then slipped by 11.21% to $311336.0 in 2026.
• The last three Accumulated Expenses figures came in at $311336.0 (Q1 2026), $350643.0 (Q4 2025), and $170426.0 (Q3 2025), per Business Quant data.